Login to Your Account

Safety Halts Reata's CKD Trial of Abbott-Partnered AIM Drug

By Jennifer Boggs
Managing Editor

Friday, October 19, 2012

Reata Pharmaceuticals Inc. ended a Phase III trial testing bardoxolone methyl in patients with Stage IV chronic kidney disease (CKD) and Type II diabetes after the independent data monitoring committee (IDMC) pointed to safety signals in the treatment arm, halting development of a drug that had once been hailed a potential blockbuster.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription